RECURSION PHARMACEUTICALS-A · held by 2 funds · data as of 2026-06-03
Sector
Healthcare
Industry
Biotechnology
Market cap
$1.92B
Price
$3.44
12-mo
-37.30%
Held by
2 funds
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-…